To the Editor The review by Dr Lin and colleagues1 provided evidence for a moderate grade level of evidence to support the
effectiveness of sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and
asthma. We would like to comment on the presentation of the included studies and the conclusion.
We performed 2 placebo-controlled studies in children with grass pollen allergy2 and house dust mite allergy3 that were included in the review as 2 of the 36 studies reporting on rhinitis
symptom scores. The authors concluded that all 36 studies demonstrated greater improvement in
rhinitis symptoms in the sublingual immunotherapy group compared with the placebo group. However,
both our grass pollen study2 and our house dust mite
study3 clearly demonstrated that there was no difference
between the 2 treatment groups with respect to all outcome measures. Therefore, we were surprised to
see that our studies were summarized as studies with improvement and would like to know how the
authors made these determinations.
Moed H, Röder E, Bindels P. Efficacy of Sublingual Immunotherapy. JAMA. 2013;310(6):644. doi:10.1001/jama.2013.7643